Liraglutide forms an effective treatment for high blood glucose levels in
type 2 diabetes mellitus
A comparison of GLP-1 agonists liraglutide and albiglutide in terms of pharmacodynamics, pharmacokinetics, and clinical relevance.
Vol. 2, no. 2, pages 35-48
Aashika Ravi, Isha Mol, Marnix van de Sande and Matthew Tan
University College Utrecht
This drug review compares two glucagon-like peptide 1 (GLP-1) agonists liraglutide and albiglutide. GLP-1 agonists are a common second-line treatment for type 2 diabetes mellitus. Drugs in this class of GLP-1 agonists make use of the incretin effect to stimulate a feedforward response for insulin secretion from the ß-cells of the pancreas. This review intends to delineate key pharmacokinetic and pharmacodynamic differences between the two drugs in order to gain a comprehensive understanding of the benefits of one treatment type over the other. Through analysis of these properties, in addition to their effectiveness in lowering plasma glucose concentration, and potential side effects, it was determined that liraglutide forms the more effective treatment for type 2 diabetes mellitus.